全文获取类型
收费全文 | 26489篇 |
免费 | 713篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 2059篇 |
妇产科学 | 286篇 |
基础医学 | 2176篇 |
口腔科学 | 103篇 |
临床医学 | 3062篇 |
内科学 | 11228篇 |
皮肤病学 | 76篇 |
神经病学 | 935篇 |
特种医学 | 1712篇 |
外科学 | 2408篇 |
综合类 | 787篇 |
一般理论 | 3篇 |
预防医学 | 964篇 |
眼科学 | 90篇 |
药学 | 916篇 |
2篇 | |
中国医学 | 76篇 |
肿瘤学 | 408篇 |
出版年
2023年 | 1175篇 |
2022年 | 2114篇 |
2021年 | 1975篇 |
2020年 | 1795篇 |
2019年 | 928篇 |
2018年 | 743篇 |
2017年 | 671篇 |
2016年 | 657篇 |
2015年 | 688篇 |
2014年 | 1863篇 |
2013年 | 1034篇 |
2012年 | 1095篇 |
2011年 | 1291篇 |
2010年 | 1452篇 |
2009年 | 1620篇 |
2008年 | 820篇 |
2007年 | 740篇 |
2006年 | 749篇 |
2005年 | 639篇 |
2004年 | 434篇 |
2003年 | 485篇 |
2002年 | 427篇 |
2001年 | 429篇 |
2000年 | 397篇 |
1999年 | 404篇 |
1998年 | 357篇 |
1997年 | 246篇 |
1996年 | 208篇 |
1995年 | 196篇 |
1994年 | 165篇 |
1993年 | 154篇 |
1992年 | 131篇 |
1991年 | 116篇 |
1990年 | 129篇 |
1989年 | 118篇 |
1988年 | 116篇 |
1987年 | 111篇 |
1986年 | 77篇 |
1985年 | 102篇 |
1984年 | 94篇 |
1983年 | 45篇 |
1982年 | 78篇 |
1981年 | 49篇 |
1980年 | 41篇 |
1979年 | 24篇 |
1978年 | 32篇 |
1977年 | 28篇 |
1976年 | 17篇 |
1975年 | 12篇 |
1974年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
《Journal of Cardiovascular Computed Tomography》2022,16(6):517-523
BackgroundSelection of the transcatheter heart valve size for a mitral valve-in-valve procedure is based on the type and manufacturer’s labelled size. However, accurate information of surgical heart valve (SHV) size may not be available in the patient’s medical record. The purpose of this study is to establish reference data for computed tomography (CT) dimensions of commonly used mitral SHV in order to determine the manufacturer’s labelled size from a cardiac CT data set.MethodsCT datasets of 105 patients with surgical mitral bioprosthesis and available manufacturer labeled datasets were included in the analysis. CT derived valve dimensions were assessed by two observers using multiplanar reformats aligned with the basal sewing ring. A circular region of interest was used in a standardized fashion to minimize influence of image acquisition and reconstruction parameters. Interobserver variability was assessed by Bland-Altman analysis.ResultsThe CT-derived dimensions were stratified by valve size and type, and SHV properties were demonstrated for 5 common valve types. Variability of measurements was small and inter-observer limits of agreement were narrow. Stratified by SHV type, no overlap was noted for CT-derived dimensions among different SHV sizes . A reference table of CT characteristics of surgical mitral bioprosthesis types was created.ConclusionThe study provides reference CT data for determining the manufacturers’ labeled SHV size across a range of commonly used mitral SHVs. The findings will be important to help identify types of surgical mitral bioprosthesis utilizing CT characteristics for patients without SHV size documentation. 相似文献
8.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(7):472-479
AimsTreatment decisions for older patients with breast cancer are complex and evidence is largely extrapolated from younger populations. Frailty and comorbidity need to be considered. We studied the baseline characteristics and treatment decisions in older patients in Christchurch with breast cancer and assessed survival outcomes and prognostic/discriminatory performance of several tools.Materials and methodsWe searched the Canterbury Breast Cancer Registry and identified patients aged 70 years or older at diagnosis with invasive, non-metastatic breast cancer between 1 June 2009 and 30 June 2015. We retrieved demographics, treatment and outcome information. Overall survival and breast cancer-specific survival were estimated. Tools analysing performance status and comorbidity were assessed for their prognostic and discriminatory power.ResultsIn total, 440 patients were identified. Primary surgery was carried out for 362 patients (82.3%): breast-conserving surgery in 114 (of whom 88.6% received radiation therapy); mastectomy in 248 (of whom 24.6% received radiation). Hormone therapy was given for 265 (71.1%) patients with oestrogen receptor-positive cancers. Two hundred and seventy-four (62.3%) patients received full standard treatment, which was associated with significantly improved 5-year survival and 5-year breast cancer-specific survival. The median estimated overall survival was 8.2 years (95% confidence interval 7.3–9.1 years). Of those who died, 71.3% of deaths were due to causes other than breast cancer or unknown causes. The comorbidity-adjusted life expectancy (CALE) showed partial prognostic accuracy. CALE, Charlson and Eastern Cooperative Oncology Group tools all showed discriminatory value.ConclusionIn this population-based series of older patients with breast cancer, showing high levels of primary and adjuvant treatment, patients were more likely to die of causes other than breast cancer. Performance status and comorbidity tools showed prognostic and discriminatory potential in this population supporting their use in treatment decision making. CALE showed the most potential to improve treatment decisions but requires validation in this population to improve prognostic accuracy. 相似文献
9.
10.